title: [Preliminary results of postoperative adjuvant treatment with tamoxifen in colorectal cancer].
abstract: OBJECTIVE
  To investigate estrogen receptor (ER) expression and the effects of anti-estrogen therapy on the prognosis of colorectal carcinoma.
  
  
  METHODS
  ER was measured in fresh colorectal cancer tissues by Dextran-coated charcoal (DCC) assay. The relationships between ER expression and clinicopathological parameters in colorectal cancer were analyzed. Tamoxifen was administrated postoperatively as adjuvant treatment.
  
  
  RESULTS
  The positive rate of ER in colorectal tumor tissues was 37.0%. The 5-year survival rates of tamoxifen group and control group were 66.7% and 72.5% respectively, and there was no significant difference between the two groups. The distant metastasis rate of Tamoxifen group was significantly lower than that of control group (3% versus 20%).
  
  
  CONCLUSIONS
  Some colorectal carcinomas are hormone-dependent tumors, and anti-estrogen therapy has no effect on them.
authors: Department of Abdominal Surgery, Cancer Center of Sun Yat-sen University, Guangzhou 510060, China. wds@medmail.com.cn
authors: De-sen
authors: DS
authors: Wan
authors: Li-ren
authors: LR
authors: Li
authors: Guo-cai
authors: GC
authors: Li
authors: Zhi-zhong
authors: ZZ
authors: Pan
authors: Zhi-wei
authors: ZW
authors: Zhou
authors: Min-shan
authors: MS
authors: Chen
authors: Ya-Qi
authors: YQ
authors: Zhang
authors: Zhi-ning
authors: ZN
authors: Gui
authors: Huai-de
authors: HD
authors: Zhang
mesh_terms: D000328:Adult; D000368:Aged; D017024:Chemotherapy, Adjuvant; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011184:Postoperative Period; D011379:Prognosis; D011960:Receptors, Estrogen / Q000378:metabolism*; D015996:Survival Rate; D013629:Tamoxifen / Q000627:therapeutic use*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D011960:Receptors, Estrogen; D013629:Tamoxifen